Skip to main content

Combinative evaluation of primary tumor and lymph nodes to predict pelvic lymphatic metastasis in cervical cancer: an integrated PET-IVIM MRI study



The aim of this study was to evaluate the value of combining pelvic lymph node and tumor characteristics on positron emission tomography-intravoxel incoherent motion magnetic resonance (PET-IVIM MR) imaging for predicting lymph node metastasis in patients with cervical cancer, especially in those with negative lymph nodes on PET.


The medical records of 95 patients with cervical cancer who underwent surgical resection with pelvic lymph node dissection were evaluated. The patients were divided into negative and positive groups according to postoperative pathologic lymph node diagnosis, and comparisons of the PET and IVIM-derived parameters between the two groups were performed. Univariate and multivariate analyses were performed to construct a predictive model of lymph node metastasis.


For all patients, tumor SUVmax, TLG, Dmin, PET and MRI for lymph node diagnosis showed significant differences between patients with and without confirmed lymph node metastasis. Univariate and multivariate logistic analysis showed that the combination of tumor TLG, Dmin and PET for lymph node diagnosis had the strongest predictive value (AUC 0.913, p < 0.001). For patients with PET-negative lymph nodes, SUVmax, SUVmean, MTV, TLG, and Dmin showed significant between-group differences, and univariate and multivariate logistic analysis showed that TLG had the strongest predictive value.


The combination of tumorTLG, Dmin and PET for lymph node diagnosis is a powerful prognostic factor for all patients. TLG has the best predictive performance in patients with PET negative lymph nodes.


Cervical cancer, one of the common malignant tumors of the female reproductive system, is a serious threat to women’s health and life [1]. Local recurrence and distant metastasis are the main causes of death. At present, treatment and prognosis plans for patients with cervical cancer are mainly based on the Federation International of Gynecology and Obstetrics (FIGO) stage. According to FIGO 2018 for cervical cancer, regardless of tumor size and parametrial infiltration, the involvement of lymph node metastasis is classified as stage IIIC. Therefore, accurate diagnosis of lymphatic metastasis is crucial for developing individualized treatment plans, improving prognosis, and reducing mortality [2,3,4].

Recently, fluoro-D-glucose (FDG)-positron emission tomography (PET) has been applied to the diagnosis of cervical cancer metastatic lymph nodes. Rather than computed tomography (CT) or magnetic resonance imaging (MRI), which identifies lymphatic metastasis according to short diameter length and morphology [5].FDG-PET provides quantified metabolic information about lymph nodes and is widely used in the evaluation of lymph node metastasis [6]. One study has proved the prognostic value of lymph node metabolism information in patients with cervical cancer [7]. A lymph node with significantly higher FDG metabolism than the background level is defined as a PET-positive lymph node [8, 9]. However, FDG is not a specific imaging agent, and lymph node reactive hyperplasia is also characterized by high metabolism resulting in many false positive cases. Also, the limited resolution of PET and partial volume effect will also affect the diagnostic accuracy of small lymph nodes.

Therefore, quantitative analysis of lymph nodes alone is ambiguous to achieve satisfied accuracy for predicting lymph node metastasis. In this study, we present a combined model (PET and intravoxel incoherent motion (IVIM)-derived imaging of primary tumors and PET/MRI diagnosis of lymphatic metastasis) for predicting lymphatic metastasis confirmed by postoperative pathology in all patients and patients with PET-negative lymph nodes.



We retrospectively collected the medical records of patients with a high suspicion of cervical cancer who had underwent PET-IVIM MRI in our hospital from April 2017 to September 2019. The study participants met the following inclusion criteria: (1) underwent surgery; (2) did not receive radiotherapy or chemotherapy before surgery; and (3) had confirmed cervical cancer via postoperative pathology.

Pathologic diagnosis

Postoperatively, the tissue was transported to the pathology department of our hospital. Hematoxylin-eosin (HE) stained sections were evaluated by two pathologists with more than 10 years of experience. The following information was recorded: lymph node metastasis, histologic tumor type, cervical stromal invasion depth, and tumor differentiation grade. The patient with one or more pelvic metastatic lymph nodes identified with pathological results was regarded as a positive case.

PET-MRI scanning and image acquisition

All patients underwent GE Signa integrated PET/MRI (Signa, GE Healthcare), which combined a 3.0 T MRI scan (GE Signa 750w) and TOF-PET, allowing simultaneous collection of both PET and MRI data. Before the examination, the patients fasted for 4 to 6 h with measured blood glucose levels lower than 7.0 mmol/L. 18F-FDG (4 MBq/kg) was injected through the cubital vein in the resting state, and PET/MRI was performed after 60 ± 12 min with a 32-channel coil (Upper Anterior Array, UAA). For PET scanning execution, a Dixon MRI sequence was used to attenuate the gamma rays, and LIST-mode and the ordered subset maximum expected iteration method were used to reconstruct the images. The MR-IVIM imaging parameters are summarized in Table 1. PET/MRI acquisition sequence and durations are shown in Fig. 1.

Table 1 Parameters used for MR-IVIM imaging
Fig. 1

PET and MRI scan at the same time, each sequence of MRI is performed in sequence, the total time is about 26 min

Image analysis

Image analysis using AW4.6 (GE Medical System) workstation was performed by 2 radiologists with more than 4 years of radiodiagnostic experience. After delineation of a lesion region of interest (ROI) at the optimal level of the PET image, the fused-PET/MRI software automatically calculated the metabolic tumor volume (MTV), total lesion glycolysis (TLG), and maximum and mean standardized uptake values (SUVmax and SUVmean) of the entire tumor. A 40% SUVmax threshold was used to calculate MTV [10, 11]. The IVIM data were analyzed using IMAgenGINE MRToolbox software (Vusion Tech Ltd). The IVIM formula was: Sb/S0 = F exp. [−b × (D* + D)] + (1-F) × exp-(b × D) [12]. On the axial T2-weighted image, the radiologists delineated ROIs at all levels of the lesion, and then the software automatically generated the volume of interest (VOIs) and copied them to the apparent diffusion coefficient (ADC) map, diffusion-related coefficient (D) map, perfusion related diffusion coefficient (D*) map, and perfusion-related parameter (f) map, obtaining the parameters ADCmean, ADCmin, Dmean, Dmin, D*, and f.

PET and MRI diagnosis of lymphatic metastasis

By comparing with surrounding background tissues, a lymph node with increased uptake by visual assessment is considered as a PET-positive lymph node, independently of node size. The method of PET image analysis was based on the previous literatures [8, 9]. Patients with one or more positive lymph nodes on PET imaging were considered to be patients with PET positive lymph nodes. Lymph nodes with short axis diameter greater than 1.0 cm and morphological characteristics on MRI were considered as MRI-positive lymph nodes [13, 14]. The results were independently evaluated by two radiologists with 12 and 13 years of experience in nuclear medicine and radiology.

Statistical analysis

The data were analyzed using MedCalc software (version 15.2.2), and a p value less than 0.05 was considered as statistical significance. The patients were divided into negative and positive group according to postoperative pathological lymph node diagnosis. Differences in lymph node diagnosis by PET/MRI between groups were evaluated using the chi-square test. The values of PET- and IVIM-derived parameters of the primary tumor were used for the quantitative statistical analyses and the between-groups comparison was performed using the t-test or Mann-Whitney U test. Interclass correlation coefficient (ICC) was used to determine the consistency of the results recorded by the two radiologists (0.8–1 indicated high consistency) [15]. Prediction models for pelvic lymph node metastasis were constructed by univariate and multivariate logistic regression (variables with p < 0.1 in the univariate analysis were used in the multivariate analysis. Bonferroni corrections were performed to correct multivariate analysis). Receiver operating characteristic (ROC) curves were generated for combined or individual parameters to assess the area under the ROC curve (AUC) for differentiating the pelvic lymph node status and obtaining the cut-off threshold values corresponding to the highest value of the Jordan index. Comparison between the ROC curves was performed with the DeLong test. The correlation between parameters was analyzed by Spearman rank correlation.


Patient characteristics

Ninety-five patients were enrolled (Fig. 2): 78 without lymph node metastasis and 17 with lymph node metastasis (Figs. 3 & 4). The clinicopathological characteristics of the participants are summarized in Table 2.

Fig. 2

Flowchart of patients who were referred to the assessment

Fig. 3

Forty-nine years-old female patient diagnosed with poorly differentiated squamous cervical carcinoma with a suspected lymph node metastasis showed on preoperative PET/MR. Postoperative pathology confirmed it as a metastatic lymph node. PET and PET/MR fusion images showed that FDG uptake in the tumor (SUVmax = 14.08 g/cm3, SUVmean = 9.35 g/cm3, TLG = 326.69 g, MTV = 34.94 cm3), and the ADC and IVIM image showed a high signal in the lymph node (ADCmean = 1.27 × 10− 3 mm2/s, ADCmin = 0.67 × 10− 3 mm2/s, Dmean = 0.97 × 10− 3 mm2/s, Dmin = 0.51 × 10− 3 mm2/s, D* = 35.92 × 10− 3 mm2/s, f = 0.17)

Fig. 4

Fifty-nine years-old female patient diagnosed moderately differentiated, squamous cervical carcinoma, with no suspected lymph node metastasis showed on preoperative PET/MR, but it showed metastatic on postoperative pathology. The primary tumor has concentrated FDG uptakes on PET/MR fusion images (SUVmax = 11.68 g/cm3, SUVmean = 7.92 g/cm3, TLG = 79.99 g, MTV = 10.1 cm3), and the ADC and IVIM image showed a high signal in the tumor (ADCmean = 1.21 × 10− 3 mm2/s, ADCmin = 0.7 × 10− 3 mm2/s, Dmean = 0.87 × 10− 3 mm2/s, Dmin = 0.5 × 10− 3 mm2/s, D* = 56.93 × 10− 3 mm2/s, f = 0.17)

Table 2 Patients’ clinicopathological characteristics

ICC statistics

Interobserver agreements were excellent for tumor SUVmax, SUVmean, MTV, TLG, ADCmean, ADCmin, Dmean, Dmin, D*, and f value (ICC,0.992, 0.991, 0.993, 0.993, 0.862, 0.822, 0.842, 0.811, 0.822 and 0.801, respectively).

The relationship between lymph node metastasis and imaging parameters in all patients

In all patients, SUVmax (p = 0.048), TLG (p = 0.014), Dmin (p = 0.020), MRI in lymph node diagnosis (p = 0.009) and PET in lymph node diagnosis (p < 0.001) showed significant differences between patients with and without lymph node metastasis (Table 3). The remaining PET- and IVIM-derived parameters did not show statistical differences between the two groups.

Table 3 The relationship between lymph node metastasis and imaging parameters in all patients

ROC analysis of the negative and positive groups according to postoperative lymph node diagnosis showed that SUVmax (AUC 0.654, p = 0.023), SUVmean (AUC 0.646, p = 0.030), TLG (AUC 0.692, p = 0.009), Dmin (AUC 0.681, p = 0.007), MRI in lymph node diagnosis (AUC 0.656, p = 0.020) and PET in lymph node diagnosis (AUC 0.736, p < 0.001) had a positive effect on predicting metastatic lymph nodes confirmed by postoperative pathology (Fig. 4). The optimal cut-off threshold values for SUVmax, SUVmean, TLG, and Dmin were 12.98 g/cm3 (sensitivity 76.47, specificity 53.85), 8.61 g/cm3 (sensitivity 70.59, specificity 60.26), 168.7 g (sensitivity 52.94, specificity 82.05), and 0.55 × 10− 3 mm2/s (sensitivity 82.35, specificity 56.41) respectively.

Univariate logistic analysis showed that MTV (p = 0.014), TLG (p = 0.019), Dmin (p = 0.026), MRI for lymph node diagnosis (p = 0.012) and PET for lymph node diagnosis (p < 0.001) were associated with lymph node metastasis. Bonferroni corrected alpha value of 0.005 per test (0.05/10) was applied to the final multivariate analyses in exploring lymph node metastasis. The combination of TLG, Dmin, and PET for lymph node diagnosis had the strongest predictive value on multivariate logistic analysis (Table 4). The area under the ROC curve for the combination of TLG, Dmin, and PET for lymph node diagnosis (AUC 0.913, p < 0.001) was higher than that of any individual parameter (p < 0.05) (Fig. 5). The correlations between parameters are shown in Table 5.

Table 4 For all patients, univariate and multivariate analysis of parameters to predict lympha metastasis
Fig. 5

For all patients, ROC analysis shows that SUVmax (AUC 0.654, 95% confidence interval (CI) 0.549–0.749, p = 0.023), SUVmean (AUC 0.646, 95% CI 0.541–0.741, p = 0.030), TLG (AUC 0.692, 95% CI 0.588–0.782, p = 0.009), Dmin (AUC 0.681, 95% CI 0.577–0.773, p = 0.007), MRI in lymph node diagnosis (AUC 0.656, 95% CI 0.551–0.750, sensitivity 58.94, specificity 78.21, p = 0.020) and PET in lymph node diagnosis (AUC 0.736, 95% CI 0.636–0.822, sensitivity 58.82, specificity 88.46, p < 0.001) had a positive effect on predicting metastatic lymph nodes confirmed by postoperative pathology. The area under the ROC curve for the combination of TLG, Dmin and PET/MRI in lymph node diagnosis (AUC 0.913, 95% CI 0.837–0.961, sensitivity 94.12, specificity 82.05, p < 0.001) was higher than any individual parameter (both, p < 0.05). CI: confidence interval

Table 5 Spearman rank correlation coefficients between parameters

The relationship between lymph node metastasis and imaging parameters in patients with PET negative lymph nodes

A total of 76 patients were evaluated: 69 without lymph node metastasis and 7 with lymph node metastasis. SUVmax (U test, p = 0.016; AUC 0.797, p < 0.001), SUVmean (U test, p = 0.018; AUC 0.792, p < 0.001), MTV (U test, p = 0.013; AUC 0.806, p = 0.024), TLG (U test, p = 0.004; AUC 0.855, p < 0.001), and Dmin (U test, p = 0.037; AUC 0.758, p = 0.005) showed significant between-group differences. The remaining parameters did not show statistical differences between the two groups. The TLG had the strongest predictive value according to the univariate and multivariate logistic analysis in the subset of patients with PET negative lymph nodes (Table 6).

Table 6 For patients with PET negative lymph nodes, univariate and multivariate analysis of parameters to predict lympha node metastasis


Recognition of lympha node metastasis before treatment in patients with cervical cancer is essential for personalized treatment plans, and diagnostic imaging is most commonly used for this purpose. In the present study, all data were measured by integrated PET-MRI. With the integrated device, a shortened scanning time, a reduced radiation dose, and the simultaneous PET and MRI parameters can be achieved, enabling combined multiparameter prediction and correlation [16,17,18,19].

The IVIM sequences was introduced into the present PET/MR study, which is an extension of diffusion-weighted imaging (DWI) sequence, to PET/MRI. DWI reflects the diffusion dynamics of tissue water molecules by ADC; however, the attenuation of DWI signals in tissues is determined by both water molecule diffusion and microcirculation perfusion. ADC is a quantitative parameter based on single index model of DWI, and it reflects both the true diffusion of water molecules and the “false diffusion”, caused by the blood microcirculation in the capillaries. This inability to reflect the movement of water molecules in living tissues limits the utility of DWI to evaluate microstructure changes.

The IVIM model compensates for these technical defects of traditional DWI. The theoretical basis is to double-exponentially fit tissue signals based on multiple b-values, and quantitatively extract the main signal attenuation components from the low b-values of the curve. The true diffusion parameter value of the tissue was calculated at high b-values [20]. So, this model has a higher accuracy to reflect the signal attenuation of water molecules than the DWI single exponential model. IVIM models can calculate three parameters, including D (purediffusion coefficient), f (perfusion fraction), and D* (pseudo-diffusion coefficient). In the IVIM model, D and f value are indicators to reflect the true diffusion coefficient and perfusion information of the molecule, respectively. IVIM modalities have also been used in other cervical cancer studies [21, 22]. However, the current IVIM technology still has shortcomings and has not been applied on a large scale in the clinic setting. The limitations include: (1) The organs in the abdominal cavity may have a slight displacement movement during long-time scans, which may affect image post-processing; (2) image distortion caused by magnetic susceptibility artifacts at the gas-soft tissue interface leads to artifacts obscuring lesions or unclear display of lesions, affecting data measurement and (3) imprecise ROIs including normal tissues result in poor measurement repeatability.

We established a combined prediction model for cervical cancer patients with lymphatic metastasis by multiple logistic regression analysis, using TLG and Dmin of the tumor and PET for lymph node diagnosis while filtering out the remaining parameters. Several mechanisms may explain the strong predictive potential of these 3 combined parameters. In previous studies, lymph node with FDG uptake more than the background lymph node metabolism level was a diagnostic criterion for lymphatic metastasis [8, 9]. Our study confirms the ability to diagnose lymphatic metastasis with this method (AUC 0.736, p < 0.001), but also demonstrates its low sensitivity (58.82). In contrast, the combination of tumor TLG and Dmin and this diagnostic criterion had better predictive value than the diagnostic criterion alone (AUC 0.913, sensitivity 94.12, specificity 82.05, p < 0.001; difference between areas 0.176, Z = 3.141, p = 0.002). Previous studies have shown that the expression of glucose transporter-1 (Glut-1) is related to lymph node metastasis in a variety of tumors [23, 24], which will trigger an increase in FDG uptake and the corresponding quantitative indicators [25]. TLG is a comprehensive parameter that reflects the metabolic activity of the whole tumor. Compared with SUVmax, TLG can assess tumor burden more accurately. A study involving patients with early cervical cancer showed that tumor MTV and TLG values are important imaging indicators for predicting lymphatic metastasis [26]. Similar conclusions have been obtained in studies involving endometrial carcinoma patients and thyroid carcinoma patients [27, 28].

Recently, many studies have quantitatively analyzed lymph nodes by IVIM to predict pelvic lymph node metastasis [29, 30]. However, the slice of IVIM imaging is thick, which makes it difficult to carry out clinically concerning the usually small volume of lymph nodes. In this study, we evaluated lymphatic metastasis using IVIM parameters of tumors for cervical cancer such as the D value. Theoretically, the D value is not affected by the microcirculation blood flow of the tumor tissue, giving a more accurate signal on the diffusion of the tissue water molecules than does the ADC value. Studies have suggested that D values correlate with hypoxia and the tumor-stroma ratios [18, 31]. Dmin value corresponds to the lowest tumor diffusion region, which may more accurately reflect the number and heterogeneity of tumor cells, as well as tumors with lymphatic metastasis.

A study using similar methods suggests that a combination of serum squamous cell carcinoma antigen (SCC-Ag) level, SUVmax, and lymph node status is an important prognostic indicator for cervical cancer [32]. Another study suggested that the combination of lymph node CT indicators and tumor TLG values can improve the accuracy of PET/CT for the diagnosis of lymphatic metastasis in patients with cervical cancer [33]. Similar combined methods are also applied to breast cancer [34].

A previous study has shown that PET/MR for lymphatic metastasis was mainly dependent on the sensitivity of PET [35]. In this study, PET was also significantly better than MR in the diagnosis of lymph nodes. But we found a large number of PET false-negative cases, which accords with the findings of endometrial cancer and non-small cell lung cancer studies [36, 37]. Identifying PET false-negative cases has always been a clinical challenge. Therefore, we further explored the relationship between lymph node metastasis and imaging parameters in patients with PET/MRI-negative lymph nodes. By multivariate logistic analysis, TLG had the strongest predictive value for lymph node metastasis in this subset of patients.

This study has several limitations. On one hand, our scan range was from the vaginal level to the upper edge of the humerus. Therefore, we could not measure the SUVpeak value which may better reflect the aggressiveness of the tumor [25]. On the other hand, we used the pathologic diagnosis as the gold standard. The inclusion of patients who have undergone surgery results in fewer negative cases in the sampled population. A further evaluation of more cases is needed to verify our conclusions.


In all patients, the combination of tumor TLG and Dmin of the tumor and PET for lymph node diagnosis had better predictive performance than the other imaging parameters for nodal metastasis. In patients with PET negative lymph nodes, TLG showed the strongest predictive potential. These findings may have clinical applications in personalized treatment planning for patients with cervical cancer.

Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.



Apparent diffusion coefficient


Computed tomography


Diffusion-related coefficient


Perfusion related diffusion coefficient


Diffusion-weighted imaging


Perfusion-related parameter




Federation International of Gynecology and Obstetrics


Glucose transporter-1




Intravoxel incoherent motion


Magnetic resonance imaging


Metabolic tumor volume


Positron emission tomography


Receiver operating characteristic


Region of interest


Serum squamous cell carcinoma antigen

SUVmax :

Maximum standardized uptake values

SUVmean :

Mean standardized uptake values


Total lesion glycolysis


  1. 1.

    Small W, Bacon MA, Bajaj A, Chuang LT, Fisher BJ, Harkenrider MM, et al. Cervical cancer: a global health crisis. Cancer. 2017;123(13):2404–12.

    Article  Google Scholar 

  2. 2.

    Forouzanfar MH, Foreman KJ, Delossantos AM, Lozano R, Lopez AD, Murray CJ, et al. Breast and cervical cancer in 187 countries between 1980 and 2010: a systematic analysis. Lancet. 2011;378(9801):1461–84.

    Article  Google Scholar 

  3. 3.

    Shim SH, Lee SW, Park JY, Kim YS, Kim DY, Kim JH, et al. Risk assessment model for overall survival in patients with locally advanced cervical cancer treated with definitive concurrent chemoradiotherapy. Gynecol Oncol. 2013;128(1):54–9.

    Article  Google Scholar 

  4. 4.

    Carlson RW, Scavone JL, Koh WJ, McClure JS, Greer BE, Kumar R, et al. NCCN framework for resource strati- fication: a framework for providing and improving global quality oncology care. J Compr Canc Netw. 2016;14(8):961–9.

    Article  Google Scholar 

  5. 5.

    Liu B, Gao S, Li S. A comprehensive comparison of CT, MRI, positron emission tomography or positron emission tomography/CT, and diffusion weighted imaging-MRI for detecting the lymph nodes metastases in patients with cervical cancer: a meta-analysis based on 67 studies. Gynecol Obstet Investig. 2017;82(3):209–22.

    CAS  Article  Google Scholar 

  6. 6.

    Grueneisen J, Schaarschmidt BM, Heubner M, Aktas B, Kinner S, Forsting M, et al. Integrated PET/MRI for whole-body staging of patients with primary cervical cancer: preliminary results. Eur J Nucl Med Mol Imaging. 2015;42(14):1814–24.

    Article  Google Scholar 

  7. 7.

    Sarker A, Im HJ, Cheon GJ, Chung HH, Kang KW, Chung JK, et al. Prognostic implications of the SUVmax of primary tumors and metastatic lymph node measured by 18F-FDG PET in patients with uterine cervical cancer: a meta-analysis. Clin Nucl Med. 2016;41(1):34–40.

    Article  Google Scholar 

  8. 8.

    Onal C, Guler OC, Reyhan M, Yapar AF. Prognostic value of 18F-fluorodeoxyglucose uptake in pelvic lymph nodes in patients with cervical cancer treated with definitive chemoradiotherapy. Gynecol Oncol. 2015;137(1):40–6.

    Article  Google Scholar 

  9. 9.

    Kitajima K, Murakami K, Yamasaki E, Kaji Y, Sugimura K. Accuracy of integrated FDG-PET/contrast-enhanced CT in detecting pelvic and paraaortic lymph node metastasis in patients with uterine cancer. Eur Radiol. 2009;19(6):1529–36.

    Article  Google Scholar 

  10. 10.

    Kidd EA, Thomas M, Siegel BA, Dehdashti F, Grigsby PW. Changes in cervical cancer FDG uptake during chemoradiation and association with response. Int J Radiat Oncol Biol Phys. 2013;85(1):116–22.

    Article  Google Scholar 

  11. 11.

    Akkas BE, Demirel BB, Dizman A, Vural GU. Do clinical characteristics and metabolic markers detected on positron emission tomography/computerized tomography associate with persistent disease in patients with in-operable cervical cancer? Ann Nucl Med. 2013;27(8):756–63.

    CAS  Article  Google Scholar 

  12. 12.

    Le Bihan D, Breton E, Lallemand D, Aubin ML, Vignaud J, Laval-Jeantet M. Separation of diffusion and perfusion in intravoxel incoherent motion MRI imaging. Radiology. 1988;168(2):497–505.

    Article  Google Scholar 

  13. 13.

    Karsten B, Johannes G, Verena R, Paul B, Bahriye A, Philipp H, et al. [18F] FDG PET/MRI vs. PET/CT for whole-body staging in patients with recurrent malignancies of the female pelvis: initial results. Eur J Nucl Med Mol Imaging. 2015;42(1):56–65.

    Article  Google Scholar 

  14. 14.

    Klerkx WM, Veldhuis WB, Spijkerboer AM, Van Den Bosch MA, Mali WP, Heintz AP, et al. The value of 3.0 tesla diffusion-weighted MRI for pelvic nodal staging in patients with early stage cervical cancer. Eur J Cancer. 2012;48(18):3414–21.

    CAS  Article  Google Scholar 

  15. 15.

    Park SO, Kim JK, Kim KA, Park BW, Kim N, Cho G, et al. Relative apparent diffusion coefficient: determination of reference site and validation of benefit for detecting metastatic lymph nodes in uterine cervical cancer. J Magn Reson Imaging. 2009;29(2):383–90.

    Article  Google Scholar 

  16. 16.

    Yoo HJ, Lee JS, Lee JM. Integrated whole body MR/PET: where are we? Korean J Radiol. 2015;16(1):32–49.

    Article  Google Scholar 

  17. 17.

    Xu C, Sun HZ, Du SY, Xin J. Early treatment response of patients undergoing concurrent chemoradiotherapy for cervical cancer: an evaluation of integrated multi-parameter PET-IVIM MR. Eur J Radiol. 2019;117:1–8.

    Article  Google Scholar 

  18. 18.

    Zhang LO, Sun HZ, Bai XX, Chen ZW, Lu ZM, Xin J, et al. Correlation between tumor glucose metabolism and multiparametric functional MRI (IVIM and R2*) metrics in cervical carcinoma: evidence from integrated 18F-FDG PET/MR. J Magn Reson Imaging. 2019;49(6):1704–12.

    Article  Google Scholar 

  19. 19.

    Du SY, Sun HZ, Gao S, Xin J, Lu ZM, Chen ZW, et al. Relationship between 18F-FDG PET metabolic parameters and MRI intravoxel incoherent motion (IVIM) histogram parameters and their correlations with clinicopathological features of cervical cancer: evidence from integrated PET/MRI. Clin Radiol. 2019;74(3):178–86.

    CAS  Article  Google Scholar 

  20. 20.

    Liu C, Liang C, Liu ZY, Zhang SX, Huang B. Intravoxel incoherent motion (IVIM) in evaluation of breast lesions: comparison with conventional DWI. Eur J Radiol. 2013;82(12):e782–9.

    Article  Google Scholar 

  21. 21.

    van Baalen S, Froeling M, Asselman M, Klazen C, Jeltes C, van Dijk L, et al. Mono, bi- and tri-exponential diffusion MRI modelling for renal solid masses and comparison with histopathological findings. Cancer Imaging. 2018;18(1):44.

    Article  Google Scholar 

  22. 22.

    Becker AS, Perucho JA, Wurnig MC, Boss A, Ghafoor S, Khong PL, et al. Assessment of cervical cancer with a parameter-free Intravoxel incoherent motion imaging algorithm. Korean J Radiol. 2017;18(3):510–8.

    Article  Google Scholar 

  23. 23.

    Yang J, Wen J, Tian T, Lu ZS, Wang Y, Wang ZK, et al. GLUT-1 overexpression as an unfavorable prognostic biomarker in patients with colorectal cancer. Oncotarget. 2016;8(7):11788–96.

    PubMed Central  Google Scholar 

  24. 24.

    Sharen GW, Peng YJ, Cheng HD, Liu Y, Shi YH, Zhao J. Prognostic value of GLUT-1 expression in pancreatic cancer: results from 538 patients. Oncotarget. 2017;8(12):19760–7.

    Article  Google Scholar 

  25. 25.

    Zhang L, Sun HZ, Du SY, Xu WN, Xin J, Guo QY. Evaluation of 18F-FDG PET/CT parameters for reflection of aggressiveness and prediction of prognosis in early-stage cervical cancer. Nucl Med Commun. 2018;39(11):1045–52.

    Article  Google Scholar 

  26. 26.

    Crivellaro C, Signorelli M, Guerra L, De Ponti E, Buda A, Dolci C, et al. 18F-FDG PET/CT can predict nodal metastases but not recurrence in early stage uterine cervical cancer. Gynecol Oncol. 2012;127(1):131–5.

    Article  Google Scholar 

  27. 27.

    Husby JA, Reitan BC, Biermann M, Trovik J, Bjørge L, Magnussen IJ, et al. Metabolic tumor volume on 18F-FDG PET/CT improves preoperative identification of high-risk endometrial carcinoma patients. J Nucl Med. 2015;56(8):1191–8.

    CAS  Article  Google Scholar 

  28. 28.

    Kim BH, Kim SJ, Kim K, Kim H, Kim SJ, Kim WJ, et al. High metabolic tumor volume and total lesion glycolysis are associated with lateral lymph node metastasis in patients with incidentally detected thyroid carcinoma. Ann Nucl Med. 2015;29(8):721–9.

    CAS  Article  Google Scholar 

  29. 29.

    Hauser T, Essig M, Jensen A, Laun FB, FBA M. Prediction of treatment response in head and neck carcinomas using IVIM-DWI: evaluation of lymph node metastasis. Eur J Radiol. 2014;83(5):783–7.

    Article  Google Scholar 

  30. 30.

    Markus S, Christiane K, Michael K, Azien Q, Maxim A, Cyrus B, et al. Preoperative evaluation of pelvine lymph node metastasis in high risk prostate cancer with intravoxel incoherent motion (IVIM) MRI. Eur J Radiol. 2018;107:1–6.

    Article  Google Scholar 

  31. 31.

    Li X, Wang P, Li D, Zhu H, Meng L, Song Y, et al. Intravoxel incoherent motion MR imaging of early cervical carcinoma: correlation between imaging parameters and tumor-stroma ratio. Eur Radiol. 2018;28(5):1875–83.

    Article  Google Scholar 

  32. 32.

    Nakamura K, Okumura Y, Kodama J, Hongo A, Kanazawa S, Hiramatsu Y. The predictive value of measurement of SUVmax and SCC-antigen in patients with pretreatment of primary squamous cellcarcinoma of cervix. Gynecol. Oncol. 2010;119(1):81–6.

    CAS  Google Scholar 

  33. 33.

    Li KX, Sun HZ, Guo QY. Combinative evaluation of primary tumor and lymph nodes in predicting pelvic lymphatic metastasis in early-stage cervical cancer: Amultiparametric PET-CT study. Eur J Radiol. 2019;113:153–7.

    Article  Google Scholar 

  34. 34.

    Song BI, Kim HW, Won KS. Predictive value of 18F-FDG PET/CT for axillary lymph node metastasis in invasive ductal breast cancer. Ann Surg Oncol. 2017;24(8):2174–81.

    Article  Google Scholar 

  35. 35.

    Heusch P, Buchbender C, Kohler J, Nensa F, Gauler T, Gomez B, et al. Thoracic staging in lung cancer: prospectivecomparison of 18F-FDG PET/MR imaging and 18F-FDG PET/CT. J Nucl Med. 2014;55(3):373–8.

    CAS  Article  Google Scholar 

  36. 36.

    Stewart KI, Chasen B, Erwin W, Fleming N, Westin SN, Dioun S, et al. Preoperative PET/CT does not accurately detect extrauterine disease in patients with newly diagnosed high-risk endometrial cancer: a prospective study. Cancer. 2019;125(19):3347–53.

    Article  Google Scholar 

  37. 37.

    Taira N, Atsumi E, Nakachi S, Takamatsu R, Yohena T, Kawasaki H, et al. Comparison of GLUT-1, SGLT-1, and SGLT-2 expression in false-negative and true-positive lymph nodes during the F-FDG PET/CT mediastinal nodal staging of non-small cell lung cancer. Lung Cancer. 2018;09:123.

    Google Scholar 

Download references


We would like to thank the native English-speaking scientists of BioMed Proofreading Company for editing our manuscript. Thanks Dr. Chengyan Dong from GE Healthcare for the revisions and language enhancement to our manuscript.


This study has received funding by National Natural Science Foundation of China (81401438), LIAONING Science & Technology Project (2017225012), LIAONING Science Natural Science Foundation (2019-MS-373) and 345 Talent Project.

Author information




Conceptualization, Chen Xu, Xiaoran Li; Methodology, Chen Xu, Xiaoran Li; Formal Analysis, Chen Xu; Investigation, Chen Xu; Resources, Chen Xu; Data Curation, Yanchi Shi, Bo Wang; Writing-Original Draft Preparation, Chen Xu; Writing –Review & Editing, Chen Xu; Supervision, Hongzan Sun; Project Administration, Hongzan Sun; Funding Acquisition, Hongzan Sun. All authors read and approved the final manuscript.

Corresponding author

Correspondence to Hongzan Sun.

Ethics declarations

Ethics approval and consent to participate

Approved by the Shengjing hospital of China Medical University Technology ethics committees.

Consent for publication

Publication is approved by all authors and tacitly or explicitly by the responsible authorities where the work was carried out.

Competing interests

The authors declare that they have no competing interests.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Xu, C., Li, X., Shi, Y. et al. Combinative evaluation of primary tumor and lymph nodes to predict pelvic lymphatic metastasis in cervical cancer: an integrated PET-IVIM MRI study. Cancer Imaging 20, 21 (2020).

Download citation


  • Cervical cancer
  • Positron-emission tomography
  • Diffusion magnetic resonance imaging
  • Lymph node